Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Bausch + Lomb Corporation

< Previous 1 2 3 Next >
Bausch + Lomb Will Participate at the 2023 Wells Fargo Healthcare Conference
From Bausch + Lomb Corporation
Via Business Wire
Tickers BLCO TSX:BLCO
Bausch + Lomb Announces Expiration of Hart-Scott-Rodino Waiting Period for Acquisition of XIIDRA®
From Bausch + Lomb Corporation
Via Business Wire
Tickers BLCO TSX:BLCO
Bausch + Lomb Announces Second-Quarter 2023 Results and Raises Full-Year 2023 Revenue Outlook
From Bausch + Lomb Corporation
Via Business Wire
Tickers BLCO TSX:BLCO
Bausch + Lomb Solidifies Leadership Team
From Bausch + Lomb Corporation
Via Business Wire
Tickers BLCO TSX:BLCO
Bausch + Lomb Will Release Second-Quarter 2023 Financial Results on August 2
From Bausch + Lomb Corporation
Via Business Wire
Tickers BLCO TSX:BLCO
Bausch + Lomb Expands OTC Product Line with Acquisition of Blink® Eye Drops
From Bausch + Lomb Corporation
Via Business Wire
Tickers BLCO TSX:BLCO
Bausch + Lomb Will Acquire XIIDRA®
From Bausch + Lomb Corporation
Via Business Wire
Tickers BLCO TSX:BLCO
Bausch + Lomb Launches PreserVision® AREDS 2 Formula Soft Gels Plus CoQ10 in the United States
From Bausch + Lomb Corporation
Via Business Wire
Tickers BLCO TSX:BLCO
Bausch + Lomb Announces New Scientific Data and Analyses Featuring Consumer, Vision Care and Pharmaceutical Products Will Be Presented During American Optometric Association's Optometry's Meeting
From Bausch + Lomb Corporation
Via Business Wire
Tickers BLCO TSX:BLCO
Bausch + Lomb Launches Biotrue® Hydration Boost Contact Lens Rehydrating Drops in the United States
From Bausch + Lomb Corporation
Via Business Wire
Tickers BLCO TSX:BLCO
Bausch + Lomb Launches Bausch + Lomb INFUSE® Multifocal Silicone Hydrogel Contact Lenses in the United States
From Bausch + Lomb Corporation
Via Business Wire
Tickers BLCO TSX:BLCO
Bausch + Lomb Announces Key Leadership Changes
From Bausch + Lomb Corporation
Via Business Wire
Tickers BLCO TSX:BLCO
Bausch + Lomb and Novaliq Announce FDA Approval of MIEBO™ (Perfluorohexyloctane Ophthalmic Solution) for the Treatment of the Signs and Symptoms of Dry Eye Disease
From Bausch + Lomb Corporation
Via Business Wire
Tickers BLCO TSX:BLCO
Bausch + Lomb Announces First-Quarter 2023 Results and Provides 2023 Guidance
From Bausch + Lomb Corporation
Via Business Wire
Tickers BLCO TSX:BLCO
Bausch + Lomb Releases Annual Environmental, Social and Governance Report
From Bausch + Lomb Corporation
Via Business Wire
Tickers BLCO TSX:BLCO
Bausch + Lomb Announces the Presentation of New Scientific Data on Products and Pipeline Programs at the American Society of Cataract and Refractive Surgery Annual Meeting
From Bausch + Lomb Corporation
Via Business Wire
Tickers BLCO TSX:BLCO
Bausch + Lomb Announces 2023 Annual Meeting of Shareholder Results
From Bausch + Lomb Corporation
Via Business Wire
Tickers BLCO TSX:BLCO
Bausch + Lomb Announces U.S. Launch of StableVisc™ Cohesive Ophthalmic Viscosurgical Device and TotalVisc™ Viscoelastic System
From Bausch + Lomb Corporation
Via Business Wire
Tickers BLCO TSX:BLCO
Bausch + Lomb Announces the Presentation of New Data on Products and Pipeline Programs at the Association for Research in Vision and Ophthalmology Meeting
From Bausch + Lomb Corporation
Via Business Wire
Tickers BLCO TSX:BLCO
Bausch + Lomb Reports More Than 65 Million Units of Contact Lens, Eye Care and Lens Care Materials Recycled Through ONE by ONE and Biotrue® Eye Care Recycling Programs
From Bausch + Lomb Corporation
Via Business Wire
Tickers BLCO TSX:BLCO
Bausch + Lomb Will Release First-Quarter 2023 Financial Results on May 3
From Bausch + Lomb Corporation
Via Business Wire
Tickers BLCO TSX:BLCO
Bausch + Lomb Appoints Bob Bailey as Executive Vice President and Chief Legal Officer and Andrew Stewart as President, Ophthalmic Pharmaceuticals
From Bausch + Lomb Corporation
Via Business Wire
Tickers BLCO TSX:BLCO
Bausch + Lomb and Novaliq Announce Publication of Second Pivotal Phase 3 Data on NOV03 (Perfluorohexyloctane) in American Journal of Ophthalmology
From Bausch + Lomb Corporation
Via Business Wire
Tickers BLCO TSX:BLCO
Bausch + Lomb Announces Fourth-Quarter and Full-Year 2022 Results
From Bausch + Lomb Corporation
Via Business Wire
Tickers BLCO TSX:BLCO
Bausch + Lomb Appoints Brent Saunders as Chief Executive Officer and Chair of the Board of Directors, Effective March 6, 2023
From Bausch + Lomb Corporation
Via Business Wire
Tickers BLCO TSX:BLCO
New Bausch + Lomb Social Media Campaign Highlights What ‘Sights’ Inspire AMD Patients
From Bausch + Lomb Corporation
Via Business Wire
Tickers BLCO TSX:BLCO
Bausch + Lomb and Modulight Announce FDA Approval of ML6710i Photodynamic Laser for Use with Bausch + Lomb’s VISUDYNE® (Verteporfin for Injection)
From Bausch + Lomb Corporation
Via Business Wire
Tickers BLCO TSX:BLCO
Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2022 Financial Results on February 22
From Bausch + Lomb Corporation
Via Business Wire
Tickers BLCO TSX:BLCO
Bausch + Lomb Acquires AcuFocus, Inc.
From Bausch + Lomb Corporation
Via Business Wire
Tickers BLCO TSX:BLCO
Bausch + Lomb Introduces Enhanced PreserVision® AREDS 2 Formula Mini Soft Gels with OCUSorb™
From Bausch + Lomb Corporation
Via Business Wire
Tickers BLCO TSX:BLCO
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.